From January 18, 2024 to March 31, 2024, the company has repurchased 2,476,300 shares, representing 0.27% for HKD 60.36 million. With this, the company has completed the repurchase of 2,476,300 shares, representing 0.27% for HKD 60.36 million under the buyback announced on January 19, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.48 CNY | +0.23% |
|
+0.25% | +12.77% |
Jun. 14 | Second Chinese drugmaker seeks approval for Ozempic generic | RE |
Jun. 13 | Sihuan Pharma Subsidiary Licenses Fadanafil Drug to Livzon Pharmaceutical Unit | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.77% | 4.42B | |
+52.93% | 803B | |
+40.98% | 629B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.42% | 244B | |
+2.17% | 226B | |
+10.66% | 215B | |
+6.24% | 164B |
- Stock Market
- Equities
- 000513 Stock
- News Livzon Pharmaceutical Group Inc.
- Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.